<DOC>
	<DOCNO>NCT00125775</DOCNO>
	<brief_summary>Hepatitis B virus cause inflammation liver detrimental end-stage renal disease patient dialysis . Hepatitis B vaccine recommend high-risk population although vaccine protection remain suboptimal last long . The purpose study determine best vaccination strategy 6-month period use recombinant hepatitis B vaccine ( Engerix-B ) peritoneal dialysis patient . Current data show traditional Engerix-B vaccine dose ( 40 microgram ) always lead protective long-lasting hepatitis B surface antibody . The investigator , therefore , decide compare usual 40-micrograms 80-microgram dose strategy vaccine protection .</brief_summary>
	<brief_title>Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection Peritoneal Dialysis Patients ?</brief_title>
	<detailed_description>The objective present randomize study evaluate optimum strategy recombinant hepatitis B vaccination maintenance protective anti-HBs antibody among end-stage renal disease patient peritoneal dialysis . This study design establish whether three-dose schedule 80 microgram Engerix-B vaccine could maintain protective antibody response among dialysis patient . The secondary aim identify effect dose various subgroup dialysis patient . Viral hepatitis B infection remain major health hazard end-stage renal disease patient dialysis . The direct cost hepatitis B infection long term impact morbidity renal transplantation substantial . Apart devastate consequence hepatitis B infection patient dialysis transplantation , infected patient potential reservoir infect patient haemodialysis staff . Antibody production achieve renal patient suboptimal ; effective method vaccination prevent hepatitis B infection end-stage renal disease subject hitherto unanswered current literature late Cochrane Collaboration review . Given relatively low seroconversion rate maintenance protective hepatitis antibody level among end-stage renal disease patient , treatment strategy use various dos recombinant hepatitis B vaccine ( Engerix-B ) recently explore . In observational study , investigator demonstrate statistically significant difference response rate patient receive three recommended dos Engerix-B intramuscularly ( 40 microgram dose ) four time normal adult dose ( 80 microgram dose ) , ( 78 % versus 100 % , P = 0.23 ) . On hand , accord Kaplan-Meier estimate , 78 percent patient 40 microgram Engerix-B vaccination group 96 percent patient 80 microgram dose group maintain seroprotective level antibody hepatitis B surface antigen ( anti-HBs ) 12 month initial response . This difference correspond absolute risk reduction 18 percent lose antibody response three-dose schedule 80 microgram Engerix-B vaccination program . In word , investigator estimate give Engerix-B 80 microgram dose would lead one extra end-stage renal disease subject persistent seroprotective anti-HBs level one year every 5.6 patient treat ( number need treat benefit NNT , 5.6 ; 95 % confidence interval , 5.4 5.8 ) .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Age 18 year Endstage renal disease maintenance peritoneal dialysis Serologically negative hepatitis B surface antigen ( HBsAg ) antibody hepatitis core antigen ( antiHBc ) No history receive hepatitis B vaccination Willingness give write informed consent willingness participate comply study protocol Expected survival le 6 month Those refused vaccination Active malignancy Alcoholic liver disease Chronic hepatitis C and/or human immunodeficiency virus ( HIV ) infection Receiving immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>